Page 2094 - Williams Hematology ( PDFDrive )

2068 Part XII: Hemostasis and Thrombosis Chapter 120: Hereditary Qualitative Platelet Disorders 2069

383. Anderson PD, Huizing M, Claassen DA, et al: Hermansky-Pudlak syndrome type 4 413. Nurden AT, Nurden P, Bermejo E, et al: Phenotypic heterogeneity in the Gray platelet
(HPS-4): Clinical and molecular characteristics. Hum Genet 113:10–17, 2003. syndrome extends to the expression of TREM family member, TLT-1. Thromb Haemost
384. Huizing M, Helip-Wooley A, Dorward H, et al: Hermansky-Pudlak syndrome: A model 100:45–51, 2008.
for abnormal vesicle formation and trafficking. Pigment Cell Res 16:584, 2003. 414. Raccuglia G: Gray platelet syndrome: A variety of qualitative platelet disorder. Am J
385. Zhang Q, Zhao B, Li W, et al: Ru2 and Ru encode mouse orthologs of the genes Med 51:818, 1971.
mutated in human Hermansky-Pudlak syndrome types 5 and 6. Nat Genet 33:145–153, 415. Maynard DM, Heijnen HF, Gahl WA, Gunay-Aygun M: The alpha granule proteome:
2003. Novel proteins in normal and ghost granules in gray platelet syndrome. J Thromb
386. Li W, Zhang Q, Oiso N, et al: Hermansky-Pudlak syndrome type 7 (HPS-7) results from Haemost 8:1786–1796, 2010.
mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 416. Zufferey A, Schvartz D, Nolli S, et al: Characterization of the platelet granule proteome:
(BLOC-1). Nat Genet 35:84–89, 2003. Evidence of the presence of MHC1 in alpha-granules. J Proteomics 101:130–140, 2014.
387. Morgan NV, Pasha S, Johnson CA, et al: A germline mutation in BLOC1S3/reduced 417. Aneja K, Jalagadugula G, Mao G, et al: Mechanism of platelet factor 4 (PF4) deficiency
pigmentation causes a novel variant of Hermansky-Pudlak syndrome (HPS8). Am with RUNX1 haplodeficiency: RUNX1 is a transcriptional regulator of PF4. J Thromb
J Hum Genet 78:160–166, 2006. Haemost 9:383–391, 2011.
388. Helip-Wooley A, Westbroek W, Dorward HM, et al: Improper trafficking of 418. Tubman VN, Levine JE, Campagna DR, et al: X-linked gray platelet syndrome due to a
melanocyte-specific proteins in Hermansky-Pudlak syndrome type-5. J Invest Derma- GATA1 Arg216Gln mutation. Blood 109:3297–3299, 2007.
tol 127:1471–1478, 2007. 419. Monteferrario D, Bolar NA, Marneth AE, et al: A dominant-negative GFI1B mutation
389. Cullinane AR, Curry JA, Carmona-Rivera C, et al: A BLOC-1 mutation screen reveals in the gray platelet syndrome. N Engl J Med 370:245–253, 2014.
that PLDN is mutated in Hermansky-Pudlak Syndrome type 9. Am J Hum Genet 420. Stevenson WS, Morel-Kopp MC, Chen Q, et al: GFI1B mutation causes a bleeding dis-
88:778–787, 2011. order with abnormal platelet function. J Thromb Haemost 11:2039–2047, 2013.
390. Michaud J, Wu F, Osato M, et al: In vitro analyses of known and novel RUNX1/AML1 421. Deppermann C, Cherpokova D, Nurden P, et al: Gray platelet syndrome and defective
mutations in dominant familial platelet disorder with predisposition to acute myelog- thrombo-inflammation in Nbeal2-deficient mice. J Clin Invest 123:3331–3342, 2013.
enous leukemia: Implications for mechanisms of pathogenesis. Blood 99:1364–1372, 422. Kahr WH, Lo RW, Li L, et al: Abnormal megakaryocyte development and platelet func-
2002. tion in Nbeal2(–/–) mice. Blood 122:3349–3358, 2013.
391. Connelly JP, Kwon EM, Gao Y, et al: Targeted correction of RUNX1 mutation in FPD 423. Lo B, Li L, Gissen P, et al: Requirement of VPS33B, a member of the Sec1/Munc18
patient-specific induced pluripotent stem cells rescues megakaryopoietic defects. Blood protein family, in megakaryocyte and platelet alpha-granule biogenesis. Blood 106:
124:1926–1930, 2014. 4159–4166, 2005.
392. Weiss HJ: Inherited disorders of platelet granules and signal transduction, in Hemosta- 424. Urban D, Li L, Christensen H, et al: The VPS33B binding protein VPS16B is required in
sis and Thrombosis: Basic Principles and Clinical Practice, 3rd ed, edited by RW Colman, megakaryocyte and platelet alpha-granule biogenesis. Blood 120:5032–5040, 2012.
J Hirsh, VJ Marder, M Samama, pp 673–684. Lippincott, Philadelphia, 1993. 425. Srivastava PC, Powling MJ, Nokes TJ, et al: Grey platelet syndrome: Studies on plate-
393. Payne CM: A qualitative ultrastructural evaluation of the cell organelle specificity of the let alpha-granules, lysosomes and defective response to thrombin. Br J Haematol 65:
uranaffin reaction to normal human platelets. Am J Clin Pathol 31:62, 1984. 441–446, 1987.
394. Weiss HJ, Lages B, Vicic W, et al: Heterogeneous abnormalities of platelet dense gran- 426. Greenberg-Sepersky SM, Simons ER, White JG: Studies of platelets from patients with
ule ultrastructure in 20 patients with congenital storage pool deficiency. Br J Haematol the grey platelet syndrome. Br J Haematol 59:603–609, 1985.
83:282–295, 1993. 427. Lages B, Sussman II, Levine SP, et al: Platelet alpha granule deficiency associated with
395. Masliah-Planchon J, Darnige L, Bellucci S: Molecular determinants of platelet delta decreased P-selectin and selective impairment of thrombin-induced activation in a new
storage pool deficiencies: An update. Br J Haematol 160:5–11, 2013. patient with gray platelet syndrome (alpha-storage pool deficiency). J Lab Clin Med
396. Akkerman JW, Nieuwenhuis HK, Mommersteeg-Leautaud ME, et al: ATP-ADP com- 129:364–375, 1997.
partmentation in storage pool deficient platelets: Correlation between granule-bound 428. Rendu F, Marche P, Hovig T, et al: Abnormal phosphoinositide metabolism and pro-
ADP and the bleeding time. Br J Haematol 55:135–143, 1983. tein phosphorylation in platelets from a patient with the grey platelet syndrome. Br J
397. Cattaneo M, Lecchi A, Agati B, et al: Evaluation of platelet function with the PFA-100 Haematol 67:199–206, 1987.
system in patients with congenital defects of platelet secretion. Thromb Res 96:213–217, 429. Baruch D, Lindhout T, Dupuy E, Caen JP: Thrombin-induced platelet factor Va forma-
1999. tion in patients with a gray platelet syndrome. Thromb Haemost 58:768–771, 1987.
398. Harrison C, Khair K, Baxter B, et al: Hermansky-Pudlak syndrome: Infrequent bleed- 430. Enouf J, Lebret M, Bredoux R, et al: Abnormal calcium transport into microsomes of
ing and first report of Turkish and Pakistani kindreds. Arch Dis Child 86:297–301, grey platelet syndrome. Br J Haematol 65:437–440, 1987.
2002. 431. Jantunen E, Hanninen A, Naukkarinen A, et al: Gray platelet syndrome with sple-
399. Hayward CP, Harrison P, Cattaneo M, et al: Platelet function analyzer (PFA)-100 clo- nomegaly and signs of extramedullary hematopoiesis: A case report with review of the
sure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost literature. Am J Hematol 46:218–224, 1994.
4:312–319, 2006. 432. Caen JP, Deschamps JF, Bodevin E, et al: Megakaryocytes and myelofibrosis in gray
400. Cattaneo M: Light transmission aggregometry and ATP release for the diagnostic platelet syndrome. Nouv Rev Fr Hematol 29:109–114, 1987.
assessment of platelet function. Semin Thromb Hemost 35:158–167, 2009. 433. Coller BS, Hultin MB, Nurden AT: Isolated alpha-granule deficiency (gray platelet syn-
401. Akkerman JWN, Nieuwenhuis HK, Mommersteeg-Leautaud ME, et al: ATP-ADP com- drome) with slight increase in bone marrow reticulin and possible glycoprotein and/or
partmentation in storage pool deficient platelets: Correlation between granule-bound protease defect. Thromb Haemost 50:211, 1983.
ADP and the bleeding time. Br J Haematol 55:135–143, 1983. 434. Falik-Zaccai TC, Anikster Y, Rivera CE, et al: A new genetic isolate of gray platelet
402. Weiss HJ, Tschopp TB, Rogers J, Brand H: Studies of platelet 5-hydroxytryptamine syndrome (GPS): Clinical, cellular, and hematologic characteristics. Mol Genet Metab
(serotonin) in storage pool disease and albinism. J Clin Invest 54:421–433, 1974. 74:303–313, 2001.
403. Weiss HJ, Lages B: Platelet malondialdehyde production and aggregation responses 435. Lages B, Shattil SJ, Bainton DF, Weiss HJ: Decreased content and surface expression of
induced by arachidonate, prostaglandin-G2, collagen, and epinephrine in 12 patients alpha-granule membrane protein GMP-140 in one of two types of platelet alpha delta
with storage pool deficiency. Blood 58:27–33, 1981. storage pool deficiency. J Clin Invest 87:919–929, 1991.
404. Witkop CJ Jr, Bowie EJ, Krumwiede MD, et al: Synergistic effect of storage pool defi- 436. Lages B, Sussman, II, et al: Platelet alpha granule deficiency associated with decreased
cient platelets and low plasma von Willebrand factor on the severity of the hemorrhagic P-selectin and selective impairment of thrombin-induced activation in a new patient with
diathesis in Hermansky-Pudlak syndrome. Am J Hematol 44:256–259, 1993. gray platelet syndrome (alpha-storage pool deficiency). J Lab Clin Med 129:364–375, 1997.
405. McKeown LP, Hansmann KE, Wilson O, et al: Platelet von Willebrand factor in 437. Blavignac J, Bunimov N, Rivard GE, Hayward CP: Quebec platelet disorder: Update on
Hermansky-Pudlak syndrome. Am J Hematol 59:115–120, 1998. pathogenesis, diagnosis, and treatment. Semin Thromb Hemost 37:713–720, 2011.
406. White JG: Electron opaque structures in human platelets: Which are or are not dense 438. Hayward CPM, Rivard GE, Kane WH: An autosomal dominant, qualitative platelet dis-
bodies? Platelets 19:455–466, 2008. order associated with multimerin deficiency, abnormalities in platelet factor V, throm-
407. Lorez HP, Richards JG, Da Prada M, et al: Storage pool disease: Comparative fluores- bospondin, von Willebrand factor, and fibrinogen, and an epinephrine aggregation
cence microscopical, cytochemical and biochemical studies on amine-storing organ- defect. Blood 87:4967–4978, 1996.
elles of human blood platelets. Br J Haematol 43:297–305, 1979. 439. Tracy PB, Giles AR, Mann KG, et al: Factor V (Quebec): A bleeding diathesis associated
408. Gordon N, Thom J, Cole C, Baker R: Rapid detection of hereditary and acquired platelet with a qualitative platelet Factor V deficiency. J Clin Invest 74:1221–1228, 1984.
storage pool deficiency by flow cytometry. Br J Haematol 89:117–123, 1995. 440. Hayward CP, Rivard GE, Kane WH, et al: An autosomal dominant, qualitative plate-
409. Nazarian R, Huizing M, Helip-Wooley A, et al: An immunoblotting assay to facili- let disorder associated with multimerin deficiency, abnormalities in platelet factor V,
tate the molecular diagnosis of Hermansky-Pudlak syndrome. Mol Genet Metab 93: thrombospondin, von Willebrand factor, and fibrinogen and an epinephrine aggrega-
134–144, 2008. tion defect. Blood 87:4967–4978, 1996.
410. Gahl WA, Brantly M, Troendle J, et al: Effect of pirfenidone on the pulmonary fibrosis 441. Veljkovic DK, Rivard GE, Diamandis M, et al: Increased expression of urokinase plas-
of Hermansky-Pudlak syndrome. Mol Genet Metab 76:234–242, 2002. minogen activator in Quebec platelet disorder is linked to megakaryocyte differentiation.
411. O’Brien K, Troendle J, Gochuico BR, et al: Pirfenidone for the treatment of Hermansky- Blood 113:1535–1542, 2009.
Pudlak syndrome pulmonary fibrosis. Mol Genet Metab 103:128–134, 2011. 442. Diamandis M, Paterson AD, Rommens JM, et al: Quebec platelet disorder is linked
412. Nurden AT, Nurden P: The gray platelet syndrome: Clinical spectrum of the disease. to the urokinase plasminogen activator gene (PLAU) and increases expression of the
Blood Rev 21:21–36, 2007. linked allele in megakaryocytes. Blood 113:1543–1546, 2009.

Kaushansky_chapter 120_p2039-2072.indd 2069 9/21/15 2:22 PM